1. Choo QL, Weiner AJ, Overby LR, et al. Isolation of a cDNA clone derived from a blood-born non-A, non-B viral hepatitis genome. Science 1989; 244: 359–62.
2. Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21: 570–83.
3. Farci P, Shimoda A, Wong D, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996; 93: 15394–15399.
4. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States. N Engl J Med 1999; 341: 556–562.
5. National Commission on Correctional Health Care, National Institute of Justice (2002). The health status of soon-to-be released inmates. Washington DC: United States Department of Justice.
6. Alter MJ, Margolis HS. Recommendations for the prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep. 1998; 47( RR-19): 1.
7. Kim WR. The burden of hepatitis C in the US. Hepatology 2002; 36: S30–S34.
8. Davis GL, Albright JE, Cook SF, et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transplant 2003; 9: 331–338.
9. Garfein RS, Vlahou D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86: 655–661.
10. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691–1696.
11. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002; 36: S93–S98.
12. Alter MJ, Coleman PJ, Alexander WJ, et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 1989; 262: 1201–1205.
13. Brettler DB, Mannucci PM, Gringeri A, et al. The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophiliac males. Blood 1992; 80: 540–543.
14. Meisel H, Reip A, Faltus B, et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet 1995; 345: 1209–1211.
15. Zylberberg H, Thiers V, Lagorce D, et al. Epidemiological and virological analysis of couples infected with hepatitis C virus. Gut 1999; 45: 112–116.
16. Stroffolini T, Lorenzoni U, Menniti-Ippolito F, et al. Hepatitis C virus infection in spouses: sexual transmission or common exposure to the same risk factors? Am J Gastroenterol 2001; 96: 3138–3141.
17. Chayama K, Kobayashi M, Tsubota A, et al. Molecular analysis of intraspousal transmission of hepatitis C virus. J Hepatol 1995; 22: 431–439.
18. Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted disease clinics in Baltimore-an analysis of 309 sex partnerships. J Infect Dis 1995; 171: 768–775.
19. Lissen E, Alter HJ, Abad MA, et al. Hepatitis C virus infection among sexually promiscuous groups and the heterosexual partners of hepatitis C virus infected index cases. Eur J Clin Microbiol Infect Dis 1993; 12: 827–831.
20. Ceci O, Margiotta M, Marello F, et al. Vertical transmission of hepatitis C in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. J Pediatr Gastroenterol Nutr 2001; 170: 103–106.
21. Healy CM, Cafferkey MT, Conroy A, et al. Outcome of infants born to hepatitis C infected women. Ir J Med Sci 2001; 170: 103–106.
22. Matubara T, Sumazaki R, Takita H. Mother-to-infant transmission of hepatitis C virus: a prospective study. Eur J Pediatr 1995; 154: 973–978.
23. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994; 330: 744–750.
24. Resti M, Azzari C, Lega L, et al. Mother-to-infant transmission of hepatitis C virus. Acta Paediatr 1995; 84: 251–255.
25. Paccagnini S, Prinicipi N, Massironi E, et al. Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population. Pediatr Infect Dis J 1995; 14: 195–199.
26. Zanetti AR, Tanzi E, Romano L, et al. A prospective study on mother-to-infant transmission of hepatitis C virus. Intervirology 1998; 41: 208–212.
27. Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. BMJ 1998; 317: 437–441.
28. Yeung LTF, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 34: 223–229.
29. Delamare C, Carbonne B, Heim N, et al. Detection of hepatitis C virus RNA in amniotic fluid: a prospective study. J Hepatol 1999; 31: 416–420.
30. Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325: 98–104.
31. Hoofnagle JH. The course and outcome of hepatitis C. Hepatology 2002; 36: S21–S29.
32. Beld M, Penning M, van Putten M, et al. Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. Blood 1999; 94: 1183–1191.
33. Barrera JM, Bruguera M, Ercilla MG, et al. Persistent hepatitis viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995; 21: 639–644.
34. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1949–1950.
35. Farci P, Alter HJ, Shimoda A, et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med 1996; 335: 631–634.
36. Mutimer D, Shaw J, Neuberger J, et al. Failure to incriminate hepatitis B, hepatitis C, and hepatitis E viruses in the aetiology of fulminant non-A, non-B hepatitis. Gut 1995; 36: 433–436.
37. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228–1233.
38. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341: 866–870.
39. Shakil AO, Conry-Canilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995; 123: 330–337.
40. Thursz M, Yallop R, Goldin R, et al. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. Lancet 1999; 354: 2119–2124.
41. Alric L, Fort M, Izopet J, et al. Genes of the major histocompatability complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997; 113: 1675–1681.
42. Gerlach JT, Diepolder HM, Zachoral R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80–88.
43. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450–456.
44. Gerlach JT, Diepolder HM, Jung MC, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999; 117: 933–941.
45. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339–344.
46. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C infection. Medicine 2000; 79: 47–56.
47. El-Serag H, Hampel H, Yeh C, et al. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002; 36: 1439–1445.
48. Andreone P, Zignego AL, Cursaro C, et al. Prevalence of monoclonal gammopathies in patients in hepatitis C virus infection. Ann Intern Med 1998; 129: 294–298.
49. Hilsabeck R, Perry W, Hassanein T. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002; 35: 440–446.
50. Forton DM, Allsop JM, Main J, et al. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001; 358: 38–39.
51. Tong MJ, el-Farra NS, Reikes AR, et al. Clinical outcomes after transfusion- associated hepatitis C. N Engl J Med 1995; 332: 1463–1466.
52. DiBisceglie AM, Goodman ZD, Ishak KG, et al. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991; 14: 969–974.
53. Benvegnu L, Pontisso P, Cavalleto D, et al. Lack of correlation between hepatitis C genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997; 25: 211–215.
54. Wong JB, Poynard T. The natural history of fibrosis in chronic hepatitis C. Hepatology. 2003; 38( Supl. 1): 182A.
55. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825–832.
56. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1–5.
57. Roudot-Thoraval F, Bastie A, Pawlotsky JM, et al. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of the Hepatitis C Virus. Hepatology 1997; 26: 485–490.
58. Gad A, Tanaka E, Orii K, et al. Relationship between hepatitis C virus infection and schistosomal liver disease: not simply an additive effect. J Gastroenterol 2001; 36: 753–758.
59. Casaril M, Stanzial AM, Tognella P, et al. Role of iron load on fibrogenesis in chronic hepatitis C. Hepatogastroenterology 2000; 47: 220–225.
60. Ortiz V, Berenguer M, Rayon JM, et al. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002; 97: 2408–2414.
61. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358–1364.
62. Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27: 1717–1722.
63. Zhang T, Li Y, Lai JP, et al. Alcohol potentiates hepatitis C virus replicon expression. Hepatology 2003; 38: 57–65.
64. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29: 1311–1316.
65. Kew MC, Mimi Cy, Kedda M, et al. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology 1997; 112: 184–187.
66. Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179–183.
67. Hamada H, Yatsuhashi H, Yano K, et al. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer 2002; 95: 331–339.
68. Yamauchi M, Nakahara M, Maezawa Y, et al. Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C. Am J Gastroenterol 1993; 88: 39–43.
69. United Network for Organ Sharing. Organ Procurement and Transplant Network (OPTN) data as of March 1, 2002. Transplants by diagnosis: January 1991 to November 2001. Available athttp://www.unos.org
. Accessed on January 10, 2003.
70. Seef LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35–S46.
71. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36: S74–S83.
72. McCormick SE, Goodman ZD, Maydonovitch CL, et al. Evaluation of liver histology, ALT elevation, and HCV RNA titer. Am J Gastroenterol 1996; 91: 1516–1522.
73. Haber MM, West AB, Haber AD, et al. Relationship of aminotransferase to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995; 90: 1250–1257.
74. Prieto M, Olaso V, Verdu C, et al. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology 1995; 22: 413–417.
75. Inglesby TV, Rai R, Astemborski J, et al. A prospective community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology 1999; 29: 590–596.
76. Pouti C, Magrini A, Statl T, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26: 1393–1398.
77. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26: 1225–1275.
78. DiBisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized double-blind, placebo controlled trial. N Engl J Med 1989; 321: 1506–1510.
79. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501–1506.
80. Alter HJ. New kid on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus. Hepatology. 1992: 350–351.
81. Pawlotsky JM. Use and interpretation of virologic tests for hepatitis C. Hepatology 2002; 36: S65–S73.
82. Cribier B, Rey D, Schmitt C, et al. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995; 9: 1131–1136.
83. Bukh J, Wantzin P, Krogsgaard K, et al. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody test to identify a significant number of patients with HCV infection. Copenhagen Dialysis HCV Study Group. J Infect Dis 1993; 168: 1343–1348.
85. Lee Sc, Antony A, Lee N, et al. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 2000; 38: 4171–4179.
86. Ross RS, Viazov SO, Hoffmann S, et al. Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitatitve detection of hepatitis C RNA. J Clin Lab Anal 2001; 15: 308–313.
87. Shiffman ML, Ferreira-Gonzalez A, Reddy KR, et al. Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice. Am J Gastroenterol 2003; 98: 1159–1166.
88. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 1485–1492.
89. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Interventional Therapy Group. Lancet 1998; 352: 1426–1432.
90. Bouier-Alias M, Patel K, Dahari H, et al. Clinical utility of total hepatitis C virus core antigen quantification, a new indirect marker of HCV replication. Hepatology 2002; 36: 211–218.
91. Lunel F, Veillon P, Payan C. Evaluation of the ortho total HCV core antigen assay in comparison to methods of detection and quantification for HCV RNA. AASLD, Boston Ma, 2002; 759A.
92. Sheth S, Flamm SL, Gordon FD, et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C infection. Am J Gastroenterol 1998; 93: 44–48.
93. Giannini E, Botta F, Fasoli A, et al. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci 1999; 44: 1249–1253.
94. Gianni E, Risso D, Botta F, et al. Validity and clinical utility of the AST/ALT ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Int Med 2003; 163: 218–224.
95. Reedy DW, Loo AT, Levine RA. AST/ALT ratio > or = l is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci 1998; 43: 2156–2159.
96. Imperiale TF, Said AT, Cummings OW, et al. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol 2000; 95: 2328–2332.
97. McHutchison JG, Blatt LM, deMedina M, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. J Gastroenterol Hepatol 2000; 15: 945–951.
98. Poynard T, McHutchison J, Manns M, et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of pegylated interferon alfa-2b and ribavirin. Hepatology 2003; 38: 481–492.
99. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334–1340.
100. Serfaty L, Poujol-Robert A, Carbonell N, et al. Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am J Gastroenterol 2002; 97: 1807–1812.
101. Yang B, Zhang B, Xu Y, et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997; 123: 357–360.
102. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002; 36( supl 1): S84–92.
103. Caturelli E, Bartolucci F, Biasini E, et al. Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. Am J Gastroenterol 2002; 97: 397–405.
104. Trevisani F, D’Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HbsAg and anti-HCV status. J Hepatol 2001; 34: 570–575.
105. Lau DT, Kleiner DE, Ghany MG, et al. Ten year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998; 28: 1121–1127.
106. Linday KL. Introduction to therapy of hepatitis C. Hepatology 2002; 36: S114–S120.
107. Shiffman ML. Pegylated interferons: what role will they play in the treatment of chronic hepatitis C? Curr Gastroenterol Rep 2001; 3: 30–37.
108. Lau JY, Davis GL, Prescott LE, et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann Intern Med 1996; 124: 868–876.
109. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
110. Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.
111. Fontaine H, Nalpas B, Poulet B, et al. Hepatitis activity is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 2001; 32: 904–909.
112. Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 2002; 34: 268–271.
113. Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136: 288–292.
114. Yawn BP, Wollan P, Gazzuola L, et al. Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. J Fam Pract 2002; 51: 135–140.
115. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961–966.
116. Kraus MR, Schafer A, Faller H, et al. Paroxetine for the treatment of interferon-alfa-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002; 16: 1091–1099.
117. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin and interferon alfa. Am J Gastroenterol 2003; 98: 2491–2499.
118. Afdhal NH, Goon B, Smith K, et al. Epoetin-alfa improves and maintains helath-related quality of life in anemic HCV-infected patients receiving interferon/ribavirin: HRQL from the Proactive Study. Hepatology. 2003; 38( supl 1): 302–303A.
119. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002. Available at http://consensus.nih.gov
. Accessed June 23, 2003.
120. Watters JK, Estilo MJ, Clark GL, et al. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA 1994; 12: 115–120.
121. Blumenthal RN, Kral AH, Gee L, et al. The effect of syringe exchange on high-risk injection drug users: a cohort study. AIDS 2000; 14: 605–611.
122. Hagan H, Des Jarlais DC, Friedman SR, et al. Reduced risk of hepatitis B and hepatitis C among infection drug users in the Tacoma Syringe Exchange Program. Am J Public Health 1995; 85: 1531–1537.
123. Hagan H, McGough JP, Thiede H, et aL. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 1999; 149: 203–213.
124. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep. 1998; 47: 1–33.
125. Terrault NA. Sexual activity as a risk factor for hepatitis C infection. Hepatology 2002; 36: S99–S105.
126. Cody SH, Nainan OV, Garfein RS, et al. Hepatitis C virus transmission from an anesthesiologist to a patient. Arch Intern Med 2002; 162: 345–350.
127. Ross RS, Viazou S, Gross T, et al. Transmission of hepatitis C virus from a patient to an anesthesiology assistant to five patients. N Engl J Med 2000; 343: 1851–1854.
128. Esteban JI, Gomez J, Martell M, et al. Transmission of hepatitis C virus by a cardiac surgeon. N Engl J Med 1996; 334: 555–560.
129. Duckworth GJ, Heptonstall J, Aitken C. Transmission of hepatitis C virus from a surgeon to a patient. Commun Dis Public Health 1999; 2: 188–192.
130. Ross RS, Viazov S, Roggendorf M. Risk of hepatitis C transmission from infected medical staff to patients: model-based calculations for surgical settings. Arch Intern Med 2000; 160: 2313–2316.
131. Associated Press. Hepatitis-infected surgeon must get consent. State directive says consent necessary before operating. Available at http://www.wnbc.com
. Accessed April 19, 2002.
132. Everhart JE, DiBisceglie AM, Murray LM, et al. Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers. Ann Intern Med 1990; 112: 544–545.
133. Hou CH, Chen WY, Kao JH, et al. Intrafamilial transmission of hepatitis C virus in hemodialysis patients. J Med Virol 1995; 45: 381–385.
134. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 286–290.
135. Papaeuangelou G, Lassopoulous N, Roumeliotou-Karayannis A, et al. Etiology of fulminant viral hepatitis in Greece. Hepatology 1984; 4: 369–372.
136. Lee WM. Acute liver failure. N Engl J Med 1993; 329: 1862–1872.
137. Arguedas MR, Heudebert GR, Fallon MB, et al. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States. Am J Gastroenterol 2002; 97: 721–728.
138. Jacobs RJ, Koss RS, Meyerhoff AS. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Am J Gastroenterol 2002; 97: 427–434.